SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in three upcoming investor conferences in January and February. B. Riley Oncology Conference Thursday, January 18, 2024 12:30PM PT/3:30PM ET Guggenheim Healthcare Talks 6th Annual Biotechnology Conference Wednesday, Febru ...